The research aims to characterize changes in ovarian and pituitary hormones associated with the development of ovarian follicular waves during the human menstrual cycle.

Start Date17 Sep 2022

Sponsor / Collaborator

University of Saskatchewan

[+1]

NCT03607409

/ CompletedNot ApplicableIIT

Role of Inhibin A as Biomarker for Ovarian Response to Stimulation With Gonadotropins for IVF Treatment

To evaluate the role of Inhibin A as bio marker for the number of mature oocytes, compared to Estradiol

Start Date09 Sep 2018

Sponsor / Collaborator

ART Fertility Clinics LLCStartup

[+1]

100 Clinical Results associated with ANSH Labs LLC

0 Patents (Medical) associated with ANSH Labs LLC

Literatures (Medical) associated with ANSH Labs LLC

01 Jun 2024·F&S reports

A novel antimüllerian gene mutation in a woman with high antral follicle count and extremely low serum antimüllerian hormone levels

Article

Author: Fatemi, Human ; Kumar, Ajay ; Melado, Laura ; Edades, Jonalyn ; Lawrenz, Barbara

Objective:

To report a case with a distinct difference between the ovarian reserve parameters of antimüllerian hormone (AMH) levels, antral follicle count (AFC), and follicle-stimulating hormone levels caused by a novel homozygous missense variant in the exon 1 of the AMH gene [NM_000479.4:c259G>A, p.(Val87Met)].

Design:

Case report.

Setting:

Tertiary referral in vitro fertilization clinic.

Patients:

A 33-year-old woman, G4P4A0E0L4, with a BMI of 25.33 kg/m², high AFC, and repeated extremely low systemic AMH levels, was detected and measured using multiple enzyme-linked immunosorbent assays.

Interventions:

Antimüllerian hormone analysis with multiple assays, whole exome sequencing through next generation sequencing to diagnose the missense variant, and inhibin B measurement.

Main Outcomes Measures:

Genetic counseling and two subsequent ovarian stimulations for successful fertility preservation.

Results:

Detection of the [NM_000479.4:c259G>A, p.(Val87Met)] variant in the AMH gene. Retrieval and cryopreservation of four euploid blastocysts and 26 metaphase II oocytes.

Conclusions:

AMH gene mutations can lead to the absence of systemic AMH levels and might be discordant to other ovarian reserve markers like AFC, follicle-stimulating hormone, and inhibin B, without affecting the ovarian response to ovarian stimulation. Clinicians should not rely exclusively on AMH levels for ovarian stimulation. When severely reduced AMH levels are found in patients with high AFC, AMH variants should be suspected, and fertility treatments should be tailored adequately.

25 Jan 2021·Human reproduction (Oxford, England)Q1 · MEDICINE

Psychosocial stress and ovarian function in adolescent and young adult cancer survivors

Q1 · MEDICINE

Article

Author: Zava, David ; Kwan, Brian ; Whitcomb, Brian W ; Shliakhtsitsava, Ksenya ; Romero, Sally A D ; Sluss, Patrick M ; Dietz, Andrew ; Natarajan, Loki ; Su, H Irene ; Kim, Jayeon

Abstract:

STUDY QUESTION:

Is psychosocial stress associated with ovarian function in reproductive-aged survivors of cancer diagnosed as adolescents and young adults (AYA survivors)?

SUMMARY ANSWER:

We observed no association between self-reported and biomarkers of psychosocial stress and ovarian function in AYA survivors.

WHAT IS KNOWN ALREADY:

Psychosocial stress suppresses hypothalamic-pituitary-ovarian axis, resulting in ovulatory dysfunction, decreased sex steroidogenesis and lower fertility in reproductive-aged women. Many cancer survivors experience high psychosocial stress and hypothalamic-pituitary-adrenal axis dysregulation. The menstrual pattern disturbances and infertility they experience have been attributed to ovarian follicle destruction, but the contribution of psychosocial stress to these phenotypes is unknown.

STUDY DESIGN, SIZE, DURATION:

A cross-sectional study was conducted estimating the association between perceived stress, measured by self-report and saliva cortisol, and ovarian function, measured by bleeding pattern, dried blood spot (DBS) FSH and LH, and saliva estradiol. We included 377 AYA survivor participants.

PARTICIPANTS/MATERIALS, SETTING, METHODS:

AYA survivor participants were ages 15–35 at cancer diagnosis and ages 18–40 at study enrollment, had completed primary cancer treatment, had a uterus and at least one ovary, did not have uncontrolled endocrinopathy and were not on hormone therapy. Recruited from cancer registries, physician referrals and cancer advocacy groups, participants provided self-reported information on psychosocial stress (Perceived Stress Scale-10 (PSS-10)) and on cancer and reproductive (fertility, contraception, menstrual pattern) characteristics. DBS samples were collected timed to the early follicular phase (cycle Days 3–7) for menstruating individuals and on a random day for amenorrheic individuals; saliva samples were collected three time points within 1 day. FSH and LH were measured by DBS ELISAs, cortisol was measured by ELISA and estradiol was measured by liquid chromatography tandem mass spectrometry.

MAIN RESULTS AND THE ROLE OF CHANCE:

The median age of participants was 34.0 years (range 19–41) at a median of 6.0 years since cancer diagnosis. The most common cancer was breast (32.1%). Median PSS-10 score was 15 (range 0–36), with 5.3% scoring ≥26, the cut point suggestive of severe stress. Cortisol levels followed a diurnal pattern and cortisol AUC was negatively correlated with PSS-10 scores (P = 0.03). Neither PSS-10 scores nor cortisol AUC were associated with FSH, LH, estradiol levels or menstrual pattern. Waking and evening cortisol and the cortisol awakening response also were not related to ovarian function measures.

LIMITATIONS, REASONS FOR CAUTION:

Our analysis is limited by its cross-sectional nature, heterogeneity of cancer diagnosis and treatments and low prevalence of severe stress.

WIDER IMPLICATIONS OF THE FINDINGS:

The lack of association between psychosocial stress and a variety of ovarian function measures in female AYA cancer survivors suggests that psychosocial stress does not have a significant impact on the reproductive axis of AYA survivors. This finding is important in counseling this population on their menstrual pattern and family building plans.

STUDY FUNDING/COMPETING INTEREST(S):

NIH HD080952, South Korea Health Industry Development Institute HI18C1837 (JK). Dr A.D. works for Bluebird Bio, Inc., Dr D.Z. works for ZRT Labs and Dr P.M.S. works for Ansh Labs, which did not sponsor, support or have oversight of this research. Other authors report no competing interests.

TRIAL REGISTRATION NUMBER:

N/A

01 Mar 2018·TheriogenologyQ2 · AGRICULTURAL & FORESTRY SCIENCE

Inhibin-A and inhibin-B in cyclic and pregnant mares, and mares with granulosa-theca cell tumors: Physiological and diagnostic implications

Q2 · AGRICULTURAL & FORESTRY SCIENCE

Article

Author: Savjani, G V ; Kumar, A ; Kalra, B ; Cotterman, R F ; Scholtz, E L ; Dujovne, G ; Legacki, E L ; Alvarenga, M A ; Ball, B A ; Conley, A J ; Uliani, R C

Studies in mares have examined serum inhibin concentrations using immuno-assays unable to distinguish dimeric inhibin-A from inhibin-B isoforms. Inhibin-A and inhibin-B immuno-assays were used to investigate concentrations in cyclic mares, young and old (6 vs 19 years old, respectively) mares following hemi-ovariectomy, mares during pregnancy and in mares with confirmed granulosa cell tumors (GCTs). Mares with inter-ovulatory intervals of 26 days had ovulatory peaks of inhibin-A averaging 80 pg/mL with a mid-cycle nadir of 5 pg/mL. Inhibin-A and inhibin-B concentrations were highly correlated (r = + 0.79, P < 0.01) though peak and nadir concentrations of inhibin-B were not significantly different. However, the ratio of inhibin-A to inhibin-B (A/B) changed significantly through the cycle, highest at ovulation and <1 (more inhibin-B than -A) at mid-cycle. Two mares with grossly extended inter-ovulatory intervals demonstrated mid-cycle inhibin-A (and inhibin-B) excursions suggestive of follicular waves. Follicle-stimulating hormone was negatively correlated with inhibin-A and -B concentrations in all 6 mares. Hemi-ovariectomy in young mares resulted in a significant decrease in inhibin-A and inhibin-B concentrations one day later (P < 0.05) but older mares did not, suggesting a possible extra-ovarian source(s) of these hormones. Both inhibin isoforms dropped to very low levels during pregnancy (P < 0.0001), inhibin-A (P < 0.0001) more rapidly than -B (P < 0.05), so that inhibin-B became the predominant measured form throughout most of gestation (P < 0.05). Mares with confirmed GCTs had elevated inhibin-B concentrations more reliably than inhibin-A but neither inhibin-A or -B was correlated with anti-Müllerian hormone concentrations. Collectively, concentrations of inhibin-A and -B were aligned with physiological events in healthy mares, though more pronounced cyclic changes were seen with inhibin-A. Inhibin-B concentrations were significantly associated with GCTs (P < 0.01), inhibin-A concentrations were not. While both inhibin-A and -B concentrations track physiological events such as cyclic follicular activity, only inhibin-B concentrations effectively signal ovarian neoplasia in mares.

News (Medical) associated with ANSH Labs LLC

06 Apr 2023

·www.businesswire.com

Global Fetal Monitoring, Diagnostics and Predictive Tests Report 2023: Sector to Reach $13.6 Billion by 2027 at a CAGR of 5.6% - ResearchAndMarkets.com

DUBLIN--( BUSINESS WIRE )--The "Fetal Monitoring, Diagnostics and Predictive Tests" report has been added to ResearchAndMarkets.com's offering. The global fetal monitoring, diagnostics and predictive tests market is expected to reach $13.6 billion by 2027 from $10.4 billion in 2022 at a CAGR of 5.6% This report aims to provide a comprehensive study of the global market for fetal monitoring, diagnostics, and predictive tests, both in terms of quantitative and qualitative data, to help businesses develop growth strategies, assess the market landscape, analyze their positions in the current marketplace, and make informed business decisions regarding fetal monitoring, diagnostics, and predictive tests. An in-depth analysis of the global fetal monitoring, diagnostics and predictive tests market includes historical data and market projections on sales by application, product type, and end user. It describes the different types of fetal monitoring, diagnostics and predictive tests and their current and historical market revenues. This report also categorizes the global fetal monitoring, diagnostics and predictive tests market based on the region (North America, Europe, and Rest of the World). Report Includes 17 data tables and 54 additional tables Detailed overview and an up-to-date analysis of the global market for fetal monitoring, prenatal diagnostics, and predictive tests Analyses of the global market trends, with historic market revenue for 2019-2021, 2022, and projections of compound annual growth rates (CAGRs) through 2027 Highlights of the current and future market potential for fetal monitoring products, diagnostic and predictive tests, along with a detailed analysis of the competitive environment, industry trends, opportunities and penetration of emerging technologies within the industry Estimation of the actual market size and revenue forecast for fetal monitoring and related markets in USD million values, and its corresponding market share analysis based on the product type, sample type, test type, end user, and region A comparative study of each category of fetal monitoring and diagnosis in addition to new technologies and developments, manufacturer and supplier competition, and the changing environment of the market due to the increasing awareness of expectant mothers Updated information on the key mergers and acquisition deals, agreements, collaborations and other impactful strategies adopted by key players in the global market for fetal monitoring products, diagnostic and predictive tests Identification of the major stakeholders and analysis of the company competitive landscape based on their recent market developments, financial performance, and segmental revenues Descriptive company profiles of the leading global players, including Abbott Laboratories, Abcam plc, Ansh Labs LLC, Beckman Coulter Inc., Contect Medical Systems Co. Ltd., and Dragerwerk AG & Co. KGaA Worldwide, there is an increase of high-risk pregnancies that has necessitated the applications of high-level fetal and maternal monitoring during pregnancies. Healthcare vendors are constantly developing and offering new technologies to meet the challenges posed by complicated pregnancies. In most developed countries, multiple births account for about 2%-4% of all live births. Though the number of multiple births has been stabilizing in recent years, in the U.S., for every 100,000 live births, 162 births have been reported to be triplets. Pregnancies have become complicated due to changes in lifestyles of women, conception after age 35 or as a teenager, obesity and diabetes in childbearing age and the success of assisted-reproduction. Physical and emotional disorders that have an impact on the health of the pregnant or postpartum individual, their baby, or both are examples of pregnancy complications. Complication-causing physical and psychological disorders can develop before, during, or after pregnancy. To reduce the risk of pregnancy difficulties, it is crucial for anybody who may become pregnant to receive medical attention before, throughout, and after pregnancy. Key Topics Covered: Chapter 1 Introduction Chapter 2 Summary and Highlights Chapter 3 Market and Technology Background 3.1 High-Risk Pregnancies 3.1.1 Advanced Maternal Age (Ama) 3.1.2 Medical Conditions Existing Before Pregnancy 3.1.3 Medical Conditions Occurring During Pregnancy 3.1.4 Pregnancy-Related Issues 3.2 Fetal Growth Restrictions 3.3 Preterm Births 3.3.1 Global Epidemiology of Preterm Births 3.3.2 Classification of Preterm Birth 3.3.3 Preterm Birth Complications 3.3.4 Causes of Preterm Birth 3.3.5 Global Rates of Preterm Births 3.4 Oligohydramnios 3.5 Abnormal Placental Blood Flow 3.6 Meconium-Stained Liquor 3.6.1 Management of Msaf 3.7 Breech Presentation 3.7.1 Fetal Heart Rate (Fhr) 3.7.2 Fetal Movement 3.7.3 Maternal Contraction 3.8 Vendors and Products for Fetal Monitoring 3.8.1 Fetoscope 3.8.2 Fetal Heart Doppler 3.8.3 Fetal Monitors 3.8.4 Fetal Scalp Electrodes 3.8.5 Telemetry 3.8.6 Fetal Pulse Oximeter 3.8.7 Fetal Ultrasound 3.8.8 Neonatal Monitoring Chapter 4 Emerging/Upcoming Technologies in the Market 4.1 Technological Advancements in Fetal Monitoring 4.1.1 Changes in Birth Technology 4.1.2 Future of Fetal Monitoring 4.1.3 New Fetal Heart Monitoring Technologies Chapter 5 Regulatory Structure 5.1 Regulatory Framework 5.1.1 United States 5.1.2 European Union (Eu) 5.1.3 Japan Chapter 6 Market Breakdown by Application 6.1 Market Analysis 6.2 Market Overview 6.3 Fetal Monitoring 6.4 Prenatal Diagnostics 6.5 Neonatal Monitoring Products Chapter 7 Impact of Covid-19 on the Market 7.1 Overview Chapter 8 Competitive Landscape 8.1 Overview 8.2 Global Company Ranking 8.3 Fetal Monitoring Industry Participants Chapter 9 Company Profiles For more information about this report visit https://www.researchandmarkets.com/r/y379y1 About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

100 Deals associated with ANSH Labs LLC

100 Translational Medicine associated with ANSH Labs LLC

Corporation Tree

Boost your research with our corporation tree data.

view full example data

Pipeline

Pipeline Snapshot as of 25 Apr 2025

No data posted

Deal

Boost your decision using our deal data.

view full example data

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Profit

Explore the financial positions of over 360K organizations with Synapse.

view full example data

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.

view full example data

Investment

Gain insights on the latest company investments from start-ups to established corporations.

view full example data

Financing

Unearth financing trends to validate and advance investment opportunities.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis